Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics (AGY): Opening the door to registration

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration 21-May-2018 / 12:25 GMT/BST Hardman & Co Research: Opening the door to registration AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCI...

Allergy Therapeutics grass allergy product meets primary objectives

Allergy Therapeutics said Monday a study to explore the safety and response of its grass allergy product drug met its prim...

Positive top-line results from Grass Ph II study

RNS Number: 6504O Allergy Therapeutics PLC 21 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly statistically significant dose-response relationship established - - Optimal Phase III dose identi...

Publication of MCT Adjuvant Data

RNS Number: 8725N Allergy Therapeutics PLC 14 May 2018 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT ), in The Journal of Immunology Novel Findings Further...

All News

DateHeadlineSource
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire
17-03-16Board ChangeRNS
14-03-16Allergy Therapeutics grants options under LTIP StockMarketWire
11-03-16Grant of Options under Long Term Incentive PlanRNS
10-03-16Broker Forecast - Panmure Gordon issues a broker note on Allergy Therapeutics PLCStockMarketWire
08-03-16Interim Results for the six months ended 31/12/15RNS
24-02-16Hardman & Co Research Report: Development ProgressRNS
23-02-16Allergy Therapeutics schedules interim resultsStockMarketWire
23-02-16Notice of Interim ResultsRNS
18-02-16Allergy Therapeutics completes patient enrolmentStockMarketWire
18-02-16Patient enrolment completed in US Phase IIb studyRNS
13-01-16Allergy Therapeutics sees double digit growth StockMarketWire
13-01-16Trading UpdateRNS
07-12-15Allergy Therapeutics initiates US phase II studyStockMarketWire
07-12-15US Phase II study for GrassMATAMPL initiatedRNS
02-12-15Holding(s) in CompanyRNS
30-11-15Allergy Therapeutics completes patient enrolmentStockMarketWire
30-11-15PQBirch204 Phase II study updateRNS
27-11-15Holding(s) in CompanyRNS
26-11-15Allergy Therapeutics grants optionsStockMarketWire
25-11-15Grant of Options under Long Term Incentive PlanRNS
18-11-15Result of AGMRNS
17-11-15Results of PlacingRNS
17-11-15Allergy Therapeutics to raise up to £12mStockMarketWire
17-11-15Proposed placing to raise up to £12 millionRNS
17-11-15Trading UpdateRNS
04-11-15Allergy Therapeutics to present at World Vaccine Congress StockMarketWire
04-11-15World Vaccine Congress PresentationRNS
21-10-15Hardman research report on Allergy TherapeuticsStockMarketWire
21-10-15Hardman & Co issues research reportRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory